The Tjoa Group has launched Meditraq to help firms across the pharmaceutical supply chain meet data requirements, one year out from the EU serialization deadline.
Ipca Laboratories, a fully-integrated Indian pharmaceutical company, has purchased an NC-based CMO in a $9.65m deal that will enable it to manufacture small volume APIs for the US market.
Celerion has integrated its proprietary electronic data acquisition system, ClinQuick, with OmniComm’s electronic data capture (EDC) solution, TrialMaster, to create a fully automated clinical trial data management platform.
PPD and Quotient Sciences have announced a new collaboration to accelerate pediatric drug development – as developing age-appropriate medicinal formulations will continue to be a focus of regulators, clinicians, and parents, says PPD senior VP.
Radiopharmaceuticals firm Telix Pharmaceuticals Limited has established a subsidiary in Japan to support clinical development and manufacturing activities.
Vector-based vaccine tech firm Vaccitech has secured £20m ($27.1m) in venture capital with investors Google Ventures, Sequoia China, Neptune Ventures and Oxford Sciences Innovation.
PRA Health Sciences has opened a new clinic in Salt Lake City, which will offer full-service early stage clinical research capabilities for healthy participants and specialized patient populations.
A natural substance found in stinging nettles and ants repeatedly attacks cancer within cells, say scientists developing low-dose alternatives to current chemotherapy drugs.
Research looks to microneedle patch to combat antimicrobial resistance
A skin patch designed to deliver antibiotics directly into the bloodstream could prevent the development of antimicrobial resistance in gut bacteria, say scientists in Ireland.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) recently established a new advisory council devoted to patient engagement.
Exclusion of brain metastasis patients from clinical trials of anti-cancer drugs could remove up to two-thirds of the stage IV population, say researchers who have published new guidelines aimed at bringing attention to opportunities for improvement.
Australia’s Therapeutic Goods Administration will reclassify all codeine products to ‘prescription only’ from February 1, in a bid to combat opioid tolerance, dependence and poisoning.
Eurodis says Brexit-related costs and admin burden placed on UK pharma may affect availability of drugs for rare diseases and discourage development of such products.
Massachusetts biopharma companies received $2.9bn in venture capital investment in 2016 – and as pressure continues to accelerate the drug development process, manufacturers will continue to turn to CROs and CMOs, says MassBio.
Optimapharm has acquired MKS Research as it plans to double its revenue and become the largest independent contract research organization (CRO) in the Central and Eastern Europe (CEE) and South East Europe (SEE) regions.
Charles River Laboratories has acquired KWS BioTest in a deal that will expand the company’s immunology contract research services and geographical footprint.
Recent changes in legislation are likely to increase the presence of foreign CMOs in China, says newly formed fill/finish firm Wuxi Griffin Pharmaceutical.
Frontida BioPharm has made an equity investment in Oncoceutics as part of a product development and commercialization agreement to advance the company's lead compound.
LabCorp’s Covance has launched a new dedicated offering for biotech, medical device, and diagnostic companies following its purchase of Chiltern in 2017.
Investment firm LeBaronBrown Llc has acquired American International Chemical Inc (AIC), a distributor of ingredients for the pharmaceutical sector and other industries.
The overhaul of the tax system will allow US pharma firms to access billions in capital, but J&J and Merck & Co. play down any changes in their M&A strategy.
Chinese patients’ concerns about the quality of locally made drugs are an opportunity for US manufacturers to increase market share according to the US-China Economic and Security Review Commission.
DNAnexus has secured $58m financing, including a strategic investment from Microsoft, in order to further develop its translational medicine solutions.
A proposed Final Rule, which would delay the implementation of the revised Common Rule, comes as a surprise to many in the institutional review board (IRB) community, says WCG compliance VP.
ChemDiv and the German Center for Neurodegenerative Diseases (DZNE) have launched a pre-commercial translational R&D program with support from Torrey Pines Investment.
McKesson Corporation has completed its acquisition of RxCrossroads to support customer needs beyond channel distribution as the industry faces increasing challenges.
Sekisui XenoTech hired in record numbers in 2017 as it anticipates 10% or higher growth over the next couple of years fueled by demand for drug-drug interaction studies.
KMT Hepatech is expanding its services with the PXB-Mouse – a humanized liver chimeric mouse model for drug discovery and development – following a strategic investment from PhoenixBio late last year.
Specialty reagent provider Maravai LifeSciences has acquired Glen Research Corporation to provide more comprehensive solutions to its customers, says VP.
INC Research/inVentiv Health is starting the new year with a rebrand after merging to create one of the largest biopharmaceutical outsourcing providers in 2017.
